TBI:NYSETrueBlue, Inc. Analysis
Data as of 2026-09-01 - not real-time
$10.49
Latest Price
9/10Risk
Risk Level: High
Executive Summary
TrueBlue, Inc. trades at $10.49, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. It has gained 22.4% over the past 30 days. Momentum indicators put RSI at 60.8 (approaching overbought) with MACD reading bearish. Price has been bracketed by support at $7.49 and resistance at $11.03.
Valuation screens as fair: a P/E of 12.8 sits below the sector average of 29.0. Consensus targets land 7.1% below where the shares trade now. Revenue is growing at 11.8% on a -3.3% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 89.8%, a beta of 0.71 and a maximum drawdown of 48.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Valuation screens as fair: a P/E of 12.8 sits below the sector average of 29.0. Consensus targets land 7.1% below where the shares trade now. Revenue is growing at 11.8% on a -3.3% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 89.8%, a beta of 0.71 and a maximum drawdown of 48.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Top Market Events
Aug 4, 2026 0 TACOMA, Wash. AP — TACOMA, Wash. AP — TrueBlue Inc. TBI on Tuesday reported a loss of $3.4 million in...Seeking Alpha27dTrueBlue, Inc. TBI Q2 2026 Earnings Call TranscriptGreetings and welcome to the TrueBlue Second Quarter...Seeking Alpha27dTrueBlue forecasts Q3 revenue growth of 7%-11% as on-demand returns to growthCEO Taryn Owen framed Q2...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 5.84
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 12.8 versus sector average of 29.0
- Trading above the 200-day average of 5.84
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 12.8 versus sector average of 29.0
- Negative profit margin of -3.3%
- Analyst targets imply -7.1% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth11.80%
Profit Margin-3.35%
P/E Ratio12.8
ROE-20.23%
ROA-2.66%
Debt/Equity54.36
P/B Ratio1.3
Op. Cash Flow$-54490000
Free Cash Flow$-38707376
Industry P/E29.0
Technical Analysis
TrendBullish
RSI60.8
Support$7.49
Resistance$11.03
MA 20$10.26
MA 50$8.68
MA 200$5.84
MACDBearish
VolumeDecreasing
Fear & Greed Index93.32
Valuation
Target Price$9.75
Upside/Downside-7.05%
GradeFair
TypeBlend
Risk Assessment
Beta0.71
Volatility89.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.